IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS

Abstract

Open access

Peer reviewed

Yousef Zakharia, Howard Colman, Frank Mott, Rimas Lukas, Nicholas Vahanian, Charles Link, Eugene Kennedy, Ramses Sadek, David Munn and Olivier Rixe

Neuro-oncology (Charlottesville, Va.), Vol.17(Suppl 5), pp.v112-v112

11/01/2015

DOI: 10.1093/neuonc/nov218.21

PMCID: PMC4638917

Files and links (1)

url

https://doi.org/10.1093/neuonc/nov218.21View

Published (Version of record) Open Access

Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology

Title: Subtitle: IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY IHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
Creators: Yousef Zakharia - University of Iowa
Howard Colman - University of Utah
Frank Mott - Georgia Regents Medical Center
Rimas Lukas - University of Chicago
Nicholas Vahanian - NewLink Genetics
Charles Link - NewLink Genetics
Eugene Kennedy - NewLink Genetics
Ramses Sadek - Georgia Regents Medical Center
David Munn - Georgia Regents Medical Center
Olivier Rixe - University of New Mexico
Resource Type: Abstract
Publication Details: Neuro-oncology (Charlottesville, Va.), Vol.17(Suppl 5), pp.v112-v112
Publisher: Oxford University Press
DOI: 10.1093/neuonc/nov218.21
PMCID: PMC4638917
ISSN: 1522-8517
eISSN: 1523-5866
Language: English
Date published: 11/01/2015
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984548265602771

2 Record Views